$heff's $tation of $tocks & $olid DD

[$heff]

HEB..$.73..The panel will be of great interest to many investors and the science community because the new FDA will emerge. The FDA that brought HEB back for an ADCOM mtng even though the company did not conduct a new PH III study like the FDA had asked. The hearing will also have public testimony where the committee members will be able to hear from patients who suffer from the debilitating consequences of Chronic Fatigue Syndrome. I think CFS could clearly emerge from the shadow similarly to what Fibromyalgia did back in the 90's. The fact that there is an ADCOM meeting in the first place shows that the FDA believes that Ampligen deserved another opportunity with the right medical & panel members to accurately assess what needs to be done for these patients who have no other options. I can see the FDA approving Ampligen on accelerated approval & making HEB conduct a confirmatory Phase III trial. This way everyone wins including the FDA & patients are not left with what they have today & that is "very restricted" options.

I will continue to watch how this trades tomorrow & Monday as it will be interesting to assess. I may trade this as a lotto play after I see the release of the notes next Tuesday. Not sure yet what I will do.

Clear post on the FDASIA and my thoughts which have not changed to drastically.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=80019726